Medical Research Stock Performance Review -- OpGen, TearLab, TrovaGene, and PRA Health Sciences

Friday, September 29, 2017 Research News
Email Print This Page Comment bookmark
Font : A-A+

NEW YORK, September 29, 2017 /PRNewswire/ --

If you want a Stock Review on OPGN, TEAR, TROV, or PRAH then come over

to and sign up for your free customized report. has issued research reports on OpGen Inc. (NASDAQ: OPGN), TearLab Corp. (NASDAQ: TEAR), TrovaGene Inc. (NASDAQ: TROV), and PRA Health Sciences
Inc. (NASDAQ: PRAH). Medical Laboratories and Research companies focus on performing various tests on patients that give them information on patients' health. These firms, as a whole, tend to offer higher dividend yields than the wider Healthcare sector. These free stocks reports are currently available on Simply sign up for your complimentary member access at:


Gaithersburg, Maryland headquartered OpGen Inc.'s stock finished Thursday's session 2.29% lower at $0.32. A total volume of 4.89 million shares was traded, which was above their three months average volume of 1.89 million shares. Over the last month, the Company's shares have advanced 26.37%. The stock is trading above its 50-day moving average by 9.85%. Moreover, shares of OpGen, which engages in developing molecular information products and services to combat infectious diseases in the healthcare industry worldwide, have a Relative Strength Index (RSI) of 59.29.

On September 08th, 2017, OpGen announced that the Company presented study results on its new rapid test in development-the Acuitas® AMR Gene Panel u5.47, and the Acuitas Lighthouse® Knowledgebase - for prediction of antibiotic susceptibility at the 2017 ASM/ESCMID Conference on Drug Development to Meet the Challenge of Antimicrobial Resistance. The poster presentation, titled "Predicting Antibiotic Resistance in Gram-Negative Bacilli by Rapid Detection of Resistance Genes," was presented by Terry Walker, Ph.D., senior vice president of research and development and the lead author on the study, on September 07th, 2017. Your complete research report on OPGN can be retrieved for free at:


Shares in San Diego, California headquartered TearLab Corp. declined 0.75%, ending yesterday's session at $1.33 with a total trading volume of 113,759 shares. The stock is trading 26.01% below its 50-day moving average. Shares of the Company, which operates as an in-vitro diagnostic company in the US, have an RSI of 32.31.  

On September 27th, 2017, TearLab announced that the Centers for Medicare & Medicaid Services has published that the preliminary reimbursement rate for the Microfluidic analysis utilizing an integrated collection and analysis device, tear osmolarity (CPT code 83861) is expected to be $22.48 per test for calendar years 2018 through 2020, which is relatively the same as the current rate of $22.66 per test. A free report on TEAR is just a click away at:


On Thursday, San Diego, California headquartered TrovaGene Inc.'s stock rose 0.71%, to close the day at $0.71. A total volume of 212,164 shares was traded. The Company's shares are trading 10.28% below their 50-day moving average. Additionally, shares of TrovaGene, which focuses on the development and commercialization of proprietary molecular genetic detection technology for use in pharmaceutical development, clinical research, and medical testing in various clinical disciplines in the US, have an RSI of 47.75.  

On September 20th, 2017, TrovaGene announced the expansion and strengthening of its Board of Directors with the appointment of Athena Countouriotis, M.D. Dr. Countouriotis brings significant experience leading clinical development programs from preclinical through clinical stages and approval. Sign up for your complimentary research report on TROV at:

PRA Health Sciences 

Shares in Raleigh, North Carolina headquartered PRA Health Sciences Inc. ended the day 0.05% higher at $75.89. A total volume of 395,401 shares was traded. The stock has gained 0.93% in the previous three months and 37.68% since the start of this year. The Company's shares are trading above their 50-day and 200-day moving averages by 0.35% and 13.28%, respectively. Furthermore, shares of PRA Health Sciences, which provides outsourced clinical development services to the biotechnology and pharmaceutical industries worldwide, have an RSI of 52.40. Register for free on and download the latest research report on PRAH at:


Daily Stock Tracker: 

Daily Stock Tracker (DST) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. DST has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below. 

DST has not been compensated; directly or indirectly; for producing or publishing this document. 


The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by DST. DST is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.  


DST, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. DST, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, DST, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. 


This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither DST nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit

CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: Phone number: (207)331-3313 Office Address: 377 Rivonia Boulevard, Rivonia, South Africa

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.


Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z


News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store